News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Protalex, Inc. (PRTX) Adds Three Industry Leaders To Clinical Development Team


5/5/2014 6:55:17 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Protalex, Inc. (OTCQB:PRTX), a clinical-stage biopharmaceutical company, announces the engagement of three senior industry leaders to advance the clinical development of the Company’s lead product candidate PRTX-100, a formulation of a proprietary, highly purified form of Staphylococcal Protein A. Joining Protalex’s leadership team are John B.L. McClain, M.D. as Medical Director, Richard J. Francovitch, Ph.D. as Vice President of ITP Programs, and Michelle Catalina, Ph.D. as Director of Preclinical Studies. Each will also join the Company’s Scientific Advisory Board (SAB).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES